| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | LARIN 1.5/30 | ETHINYL ESTRADIOL; NORETHINDRONE ACETATE | TABLET;ORAL-21 | 0.03MG;1.5MG | No | No |
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A202996-001 | LARIN 1.5/30 | ETHINYL ESTRADIOL; NORETHINDRONE ACETATE | 0.03MG;1.5MG | TABLET / ORAL-21 | AB | 2014-03-20 |
| Application-product | TE code |
|---|---|
| A202996-001 | AB |
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Larin 1.5/30 | NORETHINDRONE ACETATE/ETHINYL ESTRADIOL | Northstar Rx LLC | e232ed29-e6f5-4591-8d61-68eb8b1596f0 | 2025-12-05 | Boxed warning, Warnings, Adverse reactions | |
| Microgestin 1.5/30 | NORETHINDRONE ACETATE/ETHINYL ESTRADIOL | Mayne Pharma Inc. | 9f49a476-596c-46e1-b67b-d3d40de84216 | 2025-07-09 | Boxed warning, Warnings, Adverse reactions | |
| Microgestin 1.5/30 | NORETHINDRONE ACETATE/ETHINYL ESTRADIOL | Dr. Reddys Laboratories Inc. | 6848575e-39d8-418b-ac38-ca2793f6f367 | 2024-05-01 | Boxed warning, Warnings, Adverse reactions |
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including LARIN™ 1.5/30, are contraindicated in women who are over 35 years of age and smoke (see CONTRAINDICATIONS and WARNINGS).
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension,hyperlipidemias, obesity, and diabetes. Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks. The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined. Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population (adapted from References 8 and 9 with the author’s permission). For further information, the reader is referred to a text on epidemiological methods. 1. Thromboembolic Disorders and Other Vascular Problems a. Myocardial Infarction An increased risk of myocardial infarction has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. The relative risk of heart attack for current oral contraceptive users has been estimated to be two to six (10 to 16) . The risk is very low under the age of 30. Smoking in combination with oral contraceptive use has been shown to contribute...
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
ADVERSE REACTIONS An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS section): ● Thrombophlebitis ● Arterial thromboembolism ● Pulmonary embolism ● Myocardial infarction ● Cerebral hemorrhage ● Cerebral thrombosis ● Hypertension ● Gallbladder disease ● Hepatic adenomas or benign liver tumors Post Marketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 -1.12 (Figure 1) (70 to 74). Three studies compared breast cancer risk between current or recent COC users (
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 16714-407 | Larin 1.5/30 | Norethindrone Acetate/Ethinyl Estradiol | Northstar Rx LLC | ANDA | Current |
| 51862-872 | Microgestin 1.5/30 | Norethindrone Acetate/Ethinyl Estradiol | Mayne Pharma Inc. | ANDA | Current |
| 51862-872 | Microgestin 1.5/30 | Norethindrone Acetate/Ethinyl Estradiol | Mayne Pharma Inc. | ANDA | Current |